{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
LeMaitre Vascular, Inc.
LeMaitre Vascular Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics
LeMaitre Vascular, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 45 and a high dividend yield of 79.50%. The company's financial metrics, including ROCE and ROE, indicate strong performance, while comparisons with peers reveal a mixed competitive landscape in the Pharmaceuticals & Biotechnology sector.
LeMaitre Vascular Hits Day High with 24.41% Surge in Stock Price
LeMaitre Vascular, Inc. has seen substantial stock performance, with notable increases over various time frames, including a year-to-date rise of 40.18%. The company maintains strong financial health, highlighted by a low debt-to-equity ratio and impressive operating profit growth, alongside high institutional investor confidence.
LeMaitre Vascular Hits New 52-Week High at $115.33, Up 46.41%
LeMaitre Vascular, Inc. has achieved a new 52-week high, reflecting its strong performance with a significant increase over the past year. The company, with a market capitalization of USD 2,252 million, showcases solid financial health, impressive profit growth, and high institutional ownership, indicating strong investor confidence.
LeMaitre Vascular Experiences Revision in Stock Evaluation Amid Strong Performance Metrics
LeMaitre Vascular, Inc. has experienced notable stock price movements, currently at 113.69, with a yearly high of 115.33 and a low of 71.42. Technical indicators show mixed signals, while the company has significantly outperformed the S&P 500 across various time frames, demonstrating strong market resilience.
LeMaitre Vascular Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics
LeMaitre Vascular, Inc. has recently adjusted its valuation, with a P/E ratio of 45 and a price-to-book value of 5.84. The company boasts a high dividend yield of 78.93% and a strong ROCE of 24.61%. Despite facing year-to-date challenges, it has shown resilience over three years.
Is LeMaitre Vascular, Inc. technically bullish or bearish?
As of October 31, 2025, LeMaitre Vascular, Inc. has shifted to a bearish trend, with key indicators showing mildly bearish signals, despite a mildly bullish daily moving average, and it has underperformed the S&P 500 with a year-to-date return of -5.30%.
LeMaitre Vascular Experiences Revision in Stock Evaluation Amid Market Dynamics
LeMaitre Vascular, Inc. has recently revised its market evaluation, with its stock priced at $86.92. The company has experienced notable volatility over the past year, with a high of $109.58 and a low of $71.42. Despite recent declines, it has shown strong long-term performance, outperforming the S&P 500 over five years.
Is LeMaitre Vascular, Inc. technically bullish or bearish?
As of October 31, 2025, LeMaitre Vascular, Inc. shows a neutral technical trend with mixed signals, as it has shifted from mildly bullish to sideways, underperforming the S&P 500 with year-to-date and one-year returns of -5.67% and -8.39%, respectively.
Is LeMaitre Vascular, Inc. technically bullish or bearish?
As of October 31, 2025, LeMaitre Vascular, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 year-to-date and over one year, but outperforming it over three and five years.
Is LeMaitre Vascular, Inc. technically bullish or bearish?
As of October 31, 2025, LeMaitre Vascular, Inc. is in a neutral trend with mixed indicators, showing mild bearishness on weekly MACD and KST, while underperforming the S&P 500 year-to-date and over one year, but achieving strong three-year returns.
LeMaitre Vascular Experiences Evaluation Revision Amidst Mixed Market Signals and Strong Long-Term Performance
LeMaitre Vascular, Inc. has recently revised its evaluation amid changing market conditions. The company's stock is priced at $92.25, with a one-year return of 2.30%, trailing the S&P 500. However, it boasts a strong five-year return of 179.88%, indicating significant long-term resilience and recovery.
Is LeMaitre Vascular, Inc. technically bullish or bearish?
As of September 10, 2025, LeMaitre Vascular, Inc. shows a mildly bearish trend despite mixed signals from indicators, underperforming the S&P 500 recently but outperforming it over the past three years.
Is LeMaitre Vascular, Inc. overvalued or undervalued?
As of July 23, 2025, LeMaitre Vascular, Inc. is considered fairly valued with a P/E ratio of 45, underperforming the S&P 500, and positioned competitively among peers, but not significantly undervalued.
Is LeMaitre Vascular, Inc. overvalued or undervalued?
As of February 27, 2025, LeMaitre Vascular, Inc. is fairly valued with a P/E ratio of 45, an EV to EBITDA ratio of 30.21, and a PEG ratio of 1.43, despite mixed recent stock performance and a year-to-date return of -9.51%.
Is LeMaitre Vascular, Inc. technically bullish or bearish?
As of June 18, 2025, LeMaitre Vascular, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while mixed signals from weekly and monthly indicators suggest some bullish potential but overall prevailing bearish sentiment.
Who are in the management team of LeMaitre Vascular, Inc.?
As of March 2022, the management team of LeMaitre Vascular, Inc. includes Mr. George LeMaitre (Chairman and CEO), Mr. David Roberts (President), and Mr. Joseph Pellegrino (CFO). The Board of Directors also features independent members: Mr. Lawrence Jasinski, Mr. John O'Connor, Ms. Bridget Ross, and Mr. John Roush.
What does LeMaitre Vascular, Inc. do?
LeMaitre Vascular, Inc. is a micro-cap company that provides medical devices for treating peripheral vascular disease, with recent net sales of $60 million and a net profit of $11 million. It has a market cap of approximately $1.96 billion and key metrics include a P/E ratio of 45.00 and a dividend yield of 81.97%.
How big is LeMaitre Vascular, Inc.?
As of Jun 18, LeMaitre Vascular, Inc. has a market capitalization of $1.96 billion, with net sales of $226.26 million and net profit of $45.16 million over the latest four quarters. Shareholder's funds are $337.29 million, and total assets amount to $551.82 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
